Pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs.
The pharmacokinetics and bioavailability of acyclovir sustained-release tablets in dogs were investigated. Blood concentrations of acyclovir were determined by RP-HPLC after a single oral dose of two kinds of acyclovir tablets given separately to 6 beagle dogs. The main pharmacokinetics parameters of the acyclovir sustained-release tablet were as follows: T1/2, Tmax and Cmax were 4.10 +/- 0.20 h, 4.05 +/- 0.54 h and 6.90 +/- 0.68 [microg x ml(-1), respectively. MRT was 9.02 +/- 0.44 h. Using acyclovir standard tablet as control, relative bioavailability of the acyclovir sustained-release tablet was 152.2 +/- 49.90%. According to the two-tailed t-test, there was a distinct difference in the data for Tmax, Cmax and AUC between acyclovir sustained-release tablets and acyclovir standard tablets, and the absorbability of acyclovir sustained-release tablets was much better than that of the acyclovir standard tablets.
Yang
Qing
Q
Department of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Hu
Qin
Q
D000212:Acyclovir / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D000465:Algorithms; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D004285:Dogs; D004355:Drug Stability; D005260:Female; D005615:Freezing; D007202:Indicators and Reagents; D008297:Male; D011786:Quality Control; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets
D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D007202:Indicators and Reagents; D013607:Tablets; D000212:Acyclovir